# Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

> **NCT07708727** · PHASE2,PHASE3 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 700 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** GS-3242 Tablet
- **DRUG:** GS-3242 Injection
- **DRUG:** Lenacapavir Tablet
- **DRUG:** Lenacapavir Injection
- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT07708727
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2030-10
- **Final completion:** 2033-04
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708727, "Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07708727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*